Bharat Immunological Biological Corporation Ltd vs Ind Swift Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 16.9 as of 07 May 09:47 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of March 2022 .The P/E Ratio of Ind-Swift Ltd is 0 as of March 2022 . The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Ind-Swift Ltd is ₹ 60.61 crore as of March 2022 . The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ind-Swift Ltd for the Mar '25 is ₹ 426.19 crore as compare to the Dec '24 revenue of ₹ 122.96 crore. This represent the growth of 246.61% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Ltd for the Mar '25 is ₹ 278.4 crore as compare to the Dec '24 ebitda of ₹ 9.98 crore. This represent the growth of 2689% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Ind-Swift Ltd changed from ₹ 28.24 crore to ₹ 256.6 crore over 4 quarters. This represents a CAGR of 808.64% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2024 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2021 to 0 % on March 2024 . This represents a CAGR of 0.0% over 4 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Ind-Swift Ltd

Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and null

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Ind-Swift Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Ind-Swift Ltd is 85 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Ind-Swift Ltd?

As of May 7, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.3. On the other hand, Ind-Swift Ltd stock price is INR ₹15.7.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.